Please login to the form below

Not currently logged in
Email:
Password:

Dr Edward Browne joins Sygnature Discovery

He becomes associate director of drug metabolism and pharmacokinetics

Sygnature Discovery Dr Edward BrowneNottingham, UK-based Sygnature Discovery has expanded its drug metabolism and pharmacokinetics (DMPK) team with the appointment of Dr Edward Browne as associate director.

Dr Browne (pictured right) moves to the drug discovery service provider from GlaxoSmithKline, where he most recently served as head of DMPK for its Singapore operations.

He first joined GSK as a bioanalytical scientist in 2000, before working at Simbec Research in a similar post.

In 2005, Dr Browne re-joined GSK, becoming a team leader in its neural pathways discovery performance unit in Singapore before taking on increasingly senior roles.

Dr Timothy Schulz-Utermoehl, director of DMPK at Sygnature Discovery, said: “I am delighted to welcome Ed to the team here at Sygnature.

“Ed brings significant DMPK and drug discovery experience to our rapidly expanding department as we continue to build our CNS expertise and large molecule bio analysis.”

24th October 2016

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Valid Insight

Valid Insight is an award-winning pharmaceutical global market access consultancy....

Latest intelligence

Peter Howarth
Exploring the potential of eosinophils
GSK’s Peter Howarth talks about the emerging research that suggests there is a varied role for eosinophils...
white house
Eliminating pharmaceutical rebates, is this déjà vu?
By Andrew Parece and Matthew Majewski...
Patients are ready to embrace decentralised clinical trials, are you?
Traditional clinical trial designs simply can’t withstand the impact of COVID-19. While before the pandemic, some in clinical research were beginning to adopt virtual components, the move towards designing hybrid...

Infographics